Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore StudyFlorian H. Heidel,Andrew Charles Perkins,Andreas Reiter,Carl C. Crodel,Caroline Hasselbalch Riley,Maria Teresa Gomez-Casares,Istvan Takacs,Heiko Becker,Thomas Lehmann,Olga Vinogradova,Kate Burbury,Alessandro M. Vannucchi,Vikas Gupta,Claire Harrison,Marielle Wondergem,Jean-Jacques Kiladjian, Grace Cleary,Angela Zhang, Bruyere Mahuzier, Jagannath Kota, Anirudh Prahallad, David M. RossBlood（2022）引用 1|浏览15暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
